Page 105 - Read Online

Page 16 of 17 Rastogi. Hepatoma Res 2020;6:47 I http://dx.doi.org/10.20517/2394-5079.2020.35

2011;24:390-5.
78. Schlageter M, Terracciano LM, D’Angelo S, Sorrentino P. Histopathology of hepatocellular carcinoma. World J Gastroenterol
2014;20:15955-64.
79. Melato M, Laurino L, Mucli E, Valente M, Okuda K. Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy
study. Cancer 1989;64:455-9.
80. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology
2015;149:1226-39.e4.
81. Tretiakova MS, Shabani-Rad MT, Guggisberg K, Hart J, Andera RA, et al. Genomic and immunophenotypical differences between
hepatocellular carcinoma with and without cirrhosis. Histopathology 2010;56:683-93.
82. Tannapfel A, Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch
2002;440:345-52.
83. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15 Suppl
4:14-22.
84. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves
promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009,69:855-62.
85. Mei Y, You Y, Xia J, Gong JP, Wang YB. Identifying differentially expressed microRNAs between cirrhotic and non-cirrhotic
hepatocellular carcinoma and exploring their functions using bioinformatic analysis. Cell Physiol Biochem 2018;48:1443-56.
86. Zhang Y, Li T, Qiu Y, Zhang T, Guo P, et al. Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.
Medicine (Baltimore) 2017;96:e5642.
87. Koh YS, Kim JH, Cai H, Li LH, Kim HS, et al. Dysregulated microRNAs in non-cirrhotic hepatocellular carcinoma. Genes Genom
2013;35:759-65.
88. Chiappini F, Gross-Goupil M, Saffroy R, Azoulay D, Emile JF, et al. Microsatellite instability mutator phenotype in hepatocellular
carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004;25:541-7.
89. Togni R, Bagla N, Muiesan P, Miquel R, O'Grady J, et al. Microsatellite instability in hepatocellularcarcinoma in non-cirrhotic liver in
patients older than 60 years. Hepatol Res 2009;39:266-73.
90. Zeng W, Gouw AS, van den Heuvel MC, Molema G, Poppema S, et al. Hepatocellular carcinomas in cirrhotic and noncirrhotic human
livers share angiogenic characteristics. Ann Surg Oncol 2010;17:1564-71.
91. Kakar S, Chen X, Ho C, Burgart LJ, Sahai V, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array
comparative genomic hybridization. Mod Pathol 2009;22:134-41.
92. Grohmann M, Wiede F, Dodd GT, Gurzov EN, Ooi GJ, et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell
2018;175:1289-306.e20.
93. Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, et al. Recent insights into the multiple pathways driving non-alcoholic
steatohepatitis-derived hepatocellular carcinoma. Front Oncol 2019;9:762.
94. Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, et al. JNK1-dependent PUMA expression contributes to hepatocyte
lipoapoptosis. J Biol Chem 2009;284:26591-602.
95. Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult
hepatocellular tumors: implications for imaging and management. Radiology 2011;258:673-93.
96. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, et al. Exome sequencing of hepatocellular carcinoma identifies new

mutations signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
97. Ziol M, Pote N, Amaddeo G, Laurent A, Nault JC, et al. Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological
subtype with clinical relevance. Hepatology 2018;68:103-12.
98. Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular hepatocellular carcinoma: an aggressive subtype of hepatocellular
carcinoma. Am J Surg Pathol 2019;43:943-8.
99. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, et al. Transcriptome classification of HCC is related to gene alterations
and to new therapeutic targets. Hepatology 2007;45:42-52.
100. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2
in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12.
101. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive
histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34:1630-6.
102. Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, et al. Clinicopathological indices to predict hepatocellular carcinoma molecular
classification. Liver Int 2016;36:108-18.
103. Ando S, Shibahara J, Hayashi A, Fukayama M. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features:
immunohistochemical and mutational study. Virchows Arch 2015;467:535-42.
104. Labgaa I, Stueck A, Ward SC. Lymphoepithelioma-like carcinoma in liver. Am J Pathol 2017;187:1438-44.
105. Chan AW, Zhang Z, Chong CC, Tin EK, Chow C, et al. Genomic landscape of lymphoepithelioma-like hepatocellular carcinoma. J Pathol
2019;249:166-72.
106. Han Y, Wu Y, Yang C, Huang J, Guo Y, et al. Dynamic and specific immune responses against multiple tumor antigens were elicited in
patients with hepatocellular carcinoma after cell-based immunotherapy. J Transl Med 2017;15:64.
107. Seok JY, Na DC, Woo HG, Roncalli M, Kwon SM, et al. A fibrous stromal component in hepatocellular carcinoma reveals a
cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 2012;55:1776-86.